3DPCT Combined With CT Guided RISI in the Treatment of Thoracic Malignant Tumors

Launched by PEKING UNIVERSITY THIRD HOSPITAL · Apr 26, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring a new approach to treating thoracic (chest) malignant tumors using a method called radioactive iodine-125 seed implantation (RISI). The study focuses on improving the accuracy of this treatment by using a special tool made from 3D printing, which helps doctors place the radioactive seeds precisely where they need to go. The goal is to see if this new technique can effectively target tumors while minimizing any side effects for patients.

To participate in the trial, patients must have a diagnosed malignant tumor in their chest that is smaller than 7 centimeters and should not have widespread cancer spread throughout their body. They also need to be in good overall health with no severe underlying medical conditions. Participants can expect to receive careful monitoring throughout the treatment process to assess how well the method works and to check for any potential side effects. Overall, this study aims to make the treatment easier and more effective for patients with thoracic cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pathological diagnosis of malignant tumor of chest, lesion diameter less than 7 cm.
• • There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by early treatment.
• • No bleeding tendency, anticoagulant therapy and / or antiplatelet coagulation drugs should be stopped for at least 1 week before treatment.
• • No serious or uncontrolled underlying diseases (such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction) are found.
• • There is a suitable puncture path, and the therapeutic dose is expected to be achieved.
• • KPS \> 70, expected to tolerate puncture / seed implantation, and expected survival time greater than 3 months.
• Exclusion Criteria:
• • Severe impairment of lung function (such as FEV1 \< 40% predicted value, FVC \< 50% predicted value, DLCO \< 40% predicted value).
• • High risk of skin invasion and ulceration at the puncture site before treatment.
• • There is a large range of liquefaction and necrosis in the lesion, and the expected seed distribution would be poor.
• • Pregnant women, lactating women and mentally ill patients.
• • The patient with poor compliance and unable to complete the treatment.
• • Other conditions of the researchers who think it is not suitable to participate in this clinical trial.